CYP2D6 genotyping in natives and immigrants from the Emilia-Romagna Region (Italy)

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 11, 2011, Pages 801-806

  Riccardi, Laura N ^a   Lanzellotto, Rossana ^a   Luiselli, Donata ^a   Ceccardi, Stefania ^a   Falconi, Mirella ^a   Bini, Carla ^a   Pelotti, Susi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

AFRICA; ANTHROPOLOGY; ARTICLE; ASIA; ASIAN; BIOGEOGRAPHY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMIGRANT; IMMIGRATION; INDIGENOUS PEOPLE; ITALY; METABOLISM; MIGRATION; NEGRO; NULL ALLELE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION STRUCTURE; PRESCRIPTION; SOUTH AMERICA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; EMIGRANTS AND IMMIGRANTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPING TECHNIQUES; HUMANS; ITALY; MALE;

EMILIA;

EID: 81755184454     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0221     Document Type: Article

References (27)

1. Baye TM, Wilke RA (2010) Mapping genes that predict treatment outcome in admixed population. Pharmacogenomics J 10:465-477.
2. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharma-cogenomics 3:229-243. (Pubitemid 34223859)
3. Crescenti A, Mas S, Gassó P, et al. (2007) Simultaneous geno-typing of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clin Exp Pharmacol Physiol 34:992-997. (Pubitemid 47274547)
4. Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Phar-macogenomics and individualized drug therapy. Annu Rev Med 57:119-137.
5. Gaedigk A, Simon SD, Pearce RE, et al. (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242.
6. Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521-590. (Pubitemid 44403684)
7. Hammer Ø, Harper DAT, Ryan PD (2001) PAST: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontologia Electronica 4:9.
8. Ingelman-Sundberg M, Sim SC (2010) Pharmacogenetic bio-markers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun 396:90-94.
9. Ingelman-Sundberg M, Sim SC, Gomez A, et al. (2007) Influence of cytochrome P450 polymorphisms on drug therapies: phar-macogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. (Pubitemid 350116943)
10. Kirchheiner J (2008) CYP2D6 phenotype prediction from genotype: which system is the best?. Clin Pharmacol Ther 83: 225-227.
11. Lee SJ, Lee SS, Jung HJ, et al. (2009) Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 37:1464-1470.
12. Meyer UA (2004) Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669-676. (Pubitemid 39150124)
13. Miller MP (1997) R by C: a program that performs Fisher's exact test on any sized contingency table through the use of the Metropolis algorithm. Available at www.marksgeneticsoftware.net.
14. Nakamura K, Ariyoshi N, Yokoi T, et al. (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 293:969-973. (Pubitemid 34694136)
15. Neafsey P, Ginsberg G, Hattis D, et al. (2009) Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 12:334-361.
16. Rosenberg NA, Pritchard JK, Weber JL, et al. (2002) Genetic structure of human populations. Science 298:2381-2385. (Pubitemid 36014209)
17. Sistonen J, Fuselli S, Levo A, et al. (2005) CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 51: 1291-1295. (Pubitemid 43079419)
18. Sistonen J, Sajantila A, Lao O, et al. (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Geno-mics 17:93-101.
19. Sosa-Macías M, Elizondo G, Flores-Pérez C, et al. (2006) CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J Clin Pharmacol 46: 527-536.
20. Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169. (Pubitemid 37414228)
21. Suarez-Kurtz G (2004) Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network-REFARGEN. Pharmacogenomics J 4:347-348. (Pubitemid 39600048)
22. Suarez-Kurtz G (2008) Ethnic differences in drug therapy: a pharmacogenomics perspective. Expert Rev Clin Pharmacol 1:337-339.
23. Suarez-Kurtz G (2009) Pharmacogenomics and the genetic diversity of the Brazilian population. Cad Saúde Pública 25:1650-1651.
24. Suarez-Kurtz G (2010) Pharmacogenetics in the Brazilian population. Front Pharmacol 1:118.
25. Suarez-Kurtz G, Amorim A, Damasceno A, et al. (2010) VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics 11:1257-1267.
26. Tomalik-Scharte D, Lazar A, Fuhr U, et al. (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4-15.
27. Wennerholm A, Johansson I, Hidestrand M, et al. (2001) Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11:417-427. (Pubitemid 32656582)